Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences industry, has scheduled a conference call for Tuesday, April 18, 2023; to begin at 4:30 p.m. ET. The focus of the call will be to discuss PBIO’s 2022 financial results and provide a business update. During the call, company officials will discuss key corporate updates followed by a question-and-answer session. Those interested in accessing the call can dial (877) 545-0523 (North America) or (973) 528-0016 (international) and use the verbal access code: 519732. A replay of the call will be available on the company’s website as detailed in the press release.

In addition, Pressure BioSciences today announced financial results for Q4 and FY 2022, provided a business update and offered guidance for a strong 2023. Among the highlights, the company reported $607,000 in total revenue for Q4 2022 as compared to $315,000 for Q4 2021, an increase of 93%. “As we emerge from a challenging period of economic turbulence and strategic transition, our team has been executing strongly to bring our transformational UltraShear technology to bear on a series of major contract opportunities spanning diverse markets, from nutraceuticals to cosmeceuticals, food and beverages, agrochemicals, and more,” said Richard T. Schumacher, president and CEO of PBI. “We are confident that our pending Q1 2023 announcement of all-time record revenue for any quarter will be quickly superseded by our projected revenue growth through each succeeding quarter in 2023.”

To view the full press releases, visit https://ibn.fm/Q0ahF and https://ibn.fm/drmDq

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to SYATF are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork